Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

ADC Therapeutics SA

NYSE: ADCT · Life Sciences · 4 alerts · CIK 1771910

Share price
$1.25Close, Nov 16
Market cap
$160M
Shares outstanding
127.67MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ADC Therapeutics SA filings on SEC EDGAR ↗

4:02 PM ET 8-K
Clinical Trial Data

ADC Therapeutics Clinical Trial Data

ADC Therapeutics announced updated clinical data for ZYNLONTA from several trials, including the LOTIS-7 Phase 1b study which showed an 88.7% overall response rate and 75.3% complete response rate in relapsed or refractory large B-cell lymphoma. The data, which will be presented at the ASH Annual Meeting, also highlighted a 93% ORR in marginal zone lymphoma and results from the Phase 3 LOTIS-5 study. These findings support the company's plans to advance ZYNLONTA into Phase 3 studies for expanded indications.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.